New Delhi: The World Health Organization (WHO) on Tuesday once again postponed granting approval to India’s indigenous Covid-19 vaccine Covaxin, seeking more technical details to conduct a final ‘risk-benefit assessment’.
The global body — which was reviewing data on India’s Covaxin shot against Covid-19 to grant Emergency Use Listing (EUL) — has sought additional information from Hyderabad-based Bharat Biotech to conduct a final “risk-benefit assessment” for approving the vaccine for global use.
The organisation expects to receive the information by the “end of this week” and plans to conduct the final assessment on November 3. Bharat Biotech had submitted the request for granting EUL to the WHO on April 19, 2021.
New Delhi: The World Health Organization (WHO) on Tuesday once again postponed granting approval to India’s indigenous Covid-19 vaccine Covaxin, seeking more technical details to conduct a final ‘risk-benefit assessment’.
The global body — which was reviewing data on India’s Covaxin shot against Covid-19 to grant Emergency Use Listing (EUL) — has sought additional information from Hyderabad-based Bharat Biotech to conduct a final “risk-benefit assessment” for approving the vaccine for global use.
The organisation expects to receive the information by the “end of this week” and plans to conduct the final assessment on November 3. Bharat Biotech had submitted the request for granting EUL to the WHO on April 19, 2021.